Literature DB >> 16996237

Lymphatic mapping and sentinel node harvesting in patients with recurrent breast cancer.

R M H Roumen1, G P Kuijt, I H Liem.   

Abstract

AIMS: To evaluate the feasibility and consequences of lymphatic mapping and a ("repeat") sentinel lymph node (SLN) procedure in patients with breast cancer relapse after previous breast and axillary surgery.
METHODS: Review and presentation of a patient cohort. All SLN procedures included lymphoscintigraphy and blue dye injection technique.
RESULTS: Twelve cases are described: two patients after a previous SLN procedure and ten after a previous complete axillary lymph node dissection (ALND). Ten patients (83%) had a successful repeat SLN biopsy. After previous ALND, lymphoscintigraphy revealed drainage towards the internal mammary chain in three patients, and contralateral axillary drainage in four. Based on the information from the "repeat" SLN biopsy further treatment strategy was altered in seven of the 12 patients.
CONCLUSION: Lymphatic mapping and (repeat) SLN biopsy is possible and can be informative in patients who present with a relapse of breast cancer after previous surgery for primary breast cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16996237     DOI: 10.1016/j.ejso.2006.08.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

1.  Contralateral or bilateral lymph drainage revealed by breast lymphoscintigraphy.

Authors:  Giuseppe Trifirò; Laura Ravasi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02       Impact factor: 9.236

Review 2.  Re-sentinel node biopsy after previous breast and axillary surgery.

Authors:  Tadashi Ikeda
Journal:  Surg Today       Date:  2013-11-20       Impact factor: 2.549

Review 3.  Main controversies in breast cancer.

Authors:  Stephane Zervoudis; George Iatrakis; Eirini Tomara; Anastasia Bothou; George Papadopoulos; George Tsakiris
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Contralateral axillary lymph node metastasis and molecular changes in second primary breast cancer: a case report.

Authors:  Shuo Li; Fei Xie; Yan Li; Jue Wang; Rui Chen; Qian-Nan Zhu; Xiao-Ming Zha
Journal:  Gland Surg       Date:  2021-04

5.  Contralateral Axillary Lymph Node Metastases from Breast Carcinoma: Is it Time to Review TNM Cancer Staging?

Authors:  Francesca Magnoni; M Colleoni; D Mattar; G Corso; V Bagnardi; S Frassoni; G Santomauro; B A Jereczek-Fossa; P Veronesi; V Galimberti; V Sacchini; M Intra
Journal:  Ann Surg Oncol       Date:  2020-05-21       Impact factor: 5.344

Review 6.  Recent advances in the surgical care of breast cancer patients.

Authors:  Alessandra Mascaro; Massimo Farina; Raffaella Gigli; Carlo E Vitelli; Lucio Fortunato
Journal:  World J Surg Oncol       Date:  2010-01-20       Impact factor: 2.754

7.  Unusual Contralateral Axillary Lymph Node Metastasis in a Second Primary Breast Cancer Detected by FDG PET/CT and Lymphoscintigraphy.

Authors:  Ji-Young Kim; Hyunjong Lee; Tae Sung Kim; Han-Sung Kang; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2017-08-11

8.  Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence.

Authors:  Ingrid G M Poodt; Guusje Vugts; Adriana J G Maaskant-Braat; Robert-Jan Schipper; Adri C Voogd; Grard A P Nieuwenhuijzen
Journal:  Ann Surg Oncol       Date:  2018-03-01       Impact factor: 5.344

Review 9.  Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence: a systematic review of the literature.

Authors:  Isabell Ge; Thalia Erbes; Ingolf Juhasz-Böss
Journal:  Arch Gynecol Obstet       Date:  2022-02-04       Impact factor: 2.493

10.  Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.

Authors:  Handan Tokmak; Kerim Kaban; Mahmut Muslumanoglu; Meral Demirel; Sukru Aktan
Journal:  World J Surg Oncol       Date:  2014-07-12       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.